Pros and cons of pre-emptive screening programmes before peanut introduction in infancy.


Journal

The Lancet. Child & adolescent health
ISSN: 2352-4650
Titre abrégé: Lancet Child Adolesc Health
Pays: England
ID NLM: 101712925

Informations de publication

Date de publication:
07 2020
Historique:
received: 05 11 2019
revised: 21 01 2020
accepted: 22 01 2020
entrez: 21 6 2020
pubmed: 21 6 2020
medline: 18 8 2020
Statut: ppublish

Résumé

Peanut allergy is an important public health concern and causes substantial psychosocial comorbidity. Although fatal anaphylaxis is rare (occurring at 0·03-0·3 per million person-years in the general population), peanuts are one of the most frequent causes of food allergy mortality. The Learning Early About Peanut study transformed prevention of peanut allergy by showing that early introduction of peanut into the diet of children at high risk (ie, those with an egg allergy or severe eczema) reduced the relative risk of peanut allergy at age 5 years by 81%. Following publication of this study, the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, convened an expert panel, which recommended that, for infants with severe eczema or egg allergy, health professionals should strongly consider evaluation with peanut-specific serological IgE or skin prick test (or both) and, if necessary, an oral food challenge before peanut introduction. In the USA, depending on test results, peanut-containing foods are recommended to be introduced from age 4-6 months in infants with severe eczema or egg allergy. Early introduction to peanuts is also advocated for children with either mild to moderate or no eczema, and in children who are not allergic to egg, but without screening before peanut introduction. However, the NIAID addendum guidelines contrast with other international approaches that do not advocate for allergy screening at a population level before introducing peanuts into infants' diets. In this Review, we evaluate the advantages and disadvantages of a pre-emptive screening approach before the early introduction of peanuts in infants at high risk of peanut allergy.

Identifiants

pubmed: 32562634
pii: S2352-4642(20)30029-8
doi: 10.1016/S2352-4642(20)30029-8
pii:
doi:

Substances chimiques

Allergens 0
Immunoglobulin E 37341-29-0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

526-535

Subventions

Organisme : AHRQ HHS
ID : 5K08HS024599–02
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Elissa M Abrams (EM)

Department of Pediatrics, Section of Allergy and Clinical Immunology, University of Manitoba, Winnipeg, MB, Canada; Department of Pediatrics, Division of Allergy and Immunology, University of British Columbia, Vancouver, BC, Canada.

Helen A Brough (HA)

School of Life Course Sciences, King's College London, Children's Allergy Service, Evelina London Children's Hospital, Guy's and St Thomas' National Health Service Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London, Children's Allergy Service, Evelina London Children's Hospital, Guy's and St Thomas' National Health Service Foundation Trust, London, UK.

Corinne Keet (C)

Division of Pediatric Allergy and Immunology, Johns Hopkins School of Medicine, and Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.

Marcus S Shaker (MS)

Department of Pediatrics, Section of Allergy, Asthma and Clinical Immunology, Dartmouth Geisel School of Medicine, Lebanon, NH, USA; Department of Pediatrics, Section of Allergy, Asthma and Clinical Immunology, Children's Hospital at Dartmouth-Hitchcock, Lebanon, NH, USA.

Carina Venter (C)

Section of Allergy and Immunology, University of Colorado Denver School of Medicine, Children's Hospital Colorado, Aurora, CO, USA.

Matthew Greenhawt (M)

Section of Allergy and Immunology, University of Colorado Denver School of Medicine, Children's Hospital Colorado, Aurora, CO, USA. Electronic address: matthew.greenhawt@childrenscolorado.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH